Immunotherapy Drugs for Mesothelioma


Mesothelioma, a type of cancer typically associated with asbestos exposure, has long been difficult to treat due to its aggressive nature and the fact that it is often diagnosed at an advanced stage. Immunotherapy, which harnesses the body’s immune system to fight cancer, offers a promising new avenue for treatment.

The combination of Opdivo (nivolumab) and Yervoy (ipilimumab) has received FDA approval specifically for the treatment of inoperable malignant pleural mesothelioma. This approval was based on clinical trials that showed improved overall survival when compared to traditional chemotherapy. Patients treated with this combination experienced a median survival of 18.1 months, which is a notable improvement over the outcomes often seen with conventional treatments.

Keytruda (pembrolizumab), while not specifically approved for mesothelioma, is approved for the treatment of tumors with a high tumor mutational burden (TMB-H). This includes some mesothelioma tumors, allowing doctors to prescribe Keytruda for these patients. Clinical trials have shown that Keytruda can also lead to a median overall survival of 18 months for patients with mesothelioma, offering another potential option for those affected by this disease.

The ongoing investigation of immunotherapy drugs in clinical trials for mesothelioma is crucial. These trials not only provide valuable data on the efficacy and safety of these treatments but also offer hope for future advancements in mesothelioma therapy. Patients interested in exploring immunotherapy as a treatment option should have a thorough discussion with their oncologists. This conversation should include an evaluation of their specific case, the potential benefits and risks of immunotherapy, and whether they might be eligible for ongoing clinical trials that could provide access to cutting-edge treatments not yet widely available.